The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial
BRAF genomic alterations are the most common oncogenic drivers in pediatric low-grade glioma (pLGG). Arm 1 (n = 77) of the ongoing phase 2 FIREFLY-1 (PNOC026) trial investigated the efficacy of the oral, selective, central nervous system-penetrant, type II RAF inhibitor tovorafenib (420 mg m−2 once...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
January 2024
|
| In: |
Nature medicine
Year: 2024, Jahrgang: 30, Heft: 1, Pages: 207-217 |
| ISSN: | 1546-170X |
| DOI: | 10.1038/s41591-023-02668-y |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/s41591-023-02668-y Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/s41591-023-02668-y 
|
| Verfasserangaben: | Lindsay B. Kilburn, Dong-Anh Khuong-Quang, Jordan R. Hansford, Daniel Landi, Jasper van der Lugt, Sarah E.S. Leary, Pablo Hernáiz Driever, Simon Bailey, Sébastien Perreault, Geoffrey McCowage, Angela J. Waanders, David S. Ziegler, Olaf Witt, Patricia A. Baxter, Hyoung Jin Kang, Timothy E. Hassall, Jung Woo Han, Darren Hargrave, Andrea T. Franson, Michal Yalon Oren, Helen Toledano, Valérie Larouche, Cassie Kline, Mohamed S. Abdelbaki, Nada Jabado, Nicholas G. Gottardo, Nicolas U. Gerber, Nicholas S. Whipple, Devorah Segal, Susan N. Chi, Liat Oren, Enrica E.K. Tan, Sabine Mueller, Izzy Cornelio, Lisa McLeod, Xin Zhao, Ashley Walter, Daniel Da Costa, Peter Manley, Samuel C. Blackman, Roger J. Packer & Karsten Nysom |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1880184710 | ||
| 003 | DE-627 | ||
| 005 | 20250325050435.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240207s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41591-023-02668-y |2 doi | |
| 035 | |a (DE-627)1880184710 | ||
| 035 | |a (DE-599)KXP1880184710 | ||
| 035 | |a (OCoLC)1425200287 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Kilburn, Lindsay B. |e VerfasserIn |0 (DE-588)1318531217 |0 (DE-627)188018561X |4 aut | |
| 245 | 1 | 4 | |a The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma |b the phase 2 FIREFLY-1 trial |c Lindsay B. Kilburn, Dong-Anh Khuong-Quang, Jordan R. Hansford, Daniel Landi, Jasper van der Lugt, Sarah E.S. Leary, Pablo Hernáiz Driever, Simon Bailey, Sébastien Perreault, Geoffrey McCowage, Angela J. Waanders, David S. Ziegler, Olaf Witt, Patricia A. Baxter, Hyoung Jin Kang, Timothy E. Hassall, Jung Woo Han, Darren Hargrave, Andrea T. Franson, Michal Yalon Oren, Helen Toledano, Valérie Larouche, Cassie Kline, Mohamed S. Abdelbaki, Nada Jabado, Nicholas G. Gottardo, Nicolas U. Gerber, Nicholas S. Whipple, Devorah Segal, Susan N. Chi, Liat Oren, Enrica E.K. Tan, Sabine Mueller, Izzy Cornelio, Lisa McLeod, Xin Zhao, Ashley Walter, Daniel Da Costa, Peter Manley, Samuel C. Blackman, Roger J. Packer & Karsten Nysom |
| 264 | 1 | |c January 2024 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Veröffentlicht: 17. November 2023 | ||
| 500 | |a Gesehen am 07.02.2024 | ||
| 520 | |a BRAF genomic alterations are the most common oncogenic drivers in pediatric low-grade glioma (pLGG). Arm 1 (n = 77) of the ongoing phase 2 FIREFLY-1 (PNOC026) trial investigated the efficacy of the oral, selective, central nervous system-penetrant, type II RAF inhibitor tovorafenib (420 mg m−2 once weekly; 600 mg maximum) in patients with BRAF-altered, relapsed/refractory pLGG. Arm 2 (n = 60) is an extension cohort, which provided treatment access for patients with RAF-altered pLGG after arm 1 closure. Based on independent review, according to Response Assessment in Neuro-Oncology High-Grade Glioma (RANO-HGG) criteria, the overall response rate (ORR) of 67% met the arm 1 prespecified primary endpoint; median duration of response (DOR) was 16.6 months; and median time to response (TTR) was 3.0 months (secondary endpoints). Other select arm 1 secondary endpoints included ORR, DOR and TTR as assessed by Response Assessment in Pediatric Neuro-Oncology Low-Grade Glioma (RAPNO) criteria and safety (assessed in all treated patients and the primary endpoint for arm 2, n = 137). The ORR according to RAPNO criteria (including minor responses) was 51%; median DOR was 13.8 months; and median TTR was 5.3 months. The most common treatment-related adverse events (TRAEs) were hair color changes (76%), elevated creatine phosphokinase (56%) and anemia (49%). Grade ≥3 TRAEs occurred in 42% of patients. Nine (7%) patients had TRAEs leading to discontinuation of tovorafenib. These data indicate that tovorafenib could be an effective therapy for BRAF-altered, relapsed/refractory pLGG. ClinicalTrials.gov registration: NCT04775485. | ||
| 650 | 4 | |a Drug development | |
| 650 | 4 | |a Paediatric cancer | |
| 650 | 4 | |a Phase II trials | |
| 650 | 4 | |a Randomized controlled trials | |
| 650 | 4 | |a Targeted therapies | |
| 700 | 1 | |a Khuong-Quang, Dong-Anh |e VerfasserIn |4 aut | |
| 700 | 1 | |8 1\p |a Hansford, Jordan R. |e VerfasserIn |0 (DE-588)1350444286 |0 (DE-627)191096901X |4 aut | |
| 700 | 1 | |a Landi, Daniel |e VerfasserIn |4 aut | |
| 700 | 1 | |a van der Lugt, Jasper |e VerfasserIn |4 aut | |
| 700 | 1 | |a Leary, Sarah E. S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Driever, Pablo Hernáiz |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bailey, Simon |e VerfasserIn |4 aut | |
| 700 | 1 | |a Perreault, Sébastien |e VerfasserIn |4 aut | |
| 700 | 1 | |a McCowage, Geoffrey |e VerfasserIn |4 aut | |
| 700 | 1 | |a Waanders, Angela J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ziegler, David S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Witt, Olaf |d 1965- |e VerfasserIn |0 (DE-588)17275030X |0 (DE-627)697681750 |0 (DE-576)133607410 |4 aut | |
| 700 | 1 | |a Baxter, Patricia A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kang, Hyoung Jin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hassall, Timothy E. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Han, Jung Woo |e VerfasserIn |4 aut | |
| 700 | 1 | |8 2\p |a Hargrave, Darren R. |e VerfasserIn |0 (DE-588)1342764412 |0 (DE-627)1903094976 |4 aut | |
| 700 | 1 | |a Franson, Andrea T. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Yalon Oren, Michal |e VerfasserIn |4 aut | |
| 700 | 1 | |a Toledano, Helen |e VerfasserIn |4 aut | |
| 700 | 1 | |a Larouche, Valérie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kline, Cassie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Abdelbaki, Mohamed S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jabado, Nada |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gottardo, Nicholas G. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gerber, Nicolas U. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Whipple, Nicholas S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Segal, Devorah |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chi, Susan N. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Oren, Liat |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tan, Enrica E. K. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Müller, Sabine |d 1971- |e VerfasserIn |0 (DE-588)129903523 |0 (DE-627)0483350222 |0 (DE-576)302562214 |4 aut | |
| 700 | 1 | |a Cornelio, Izzy |e VerfasserIn |4 aut | |
| 700 | 1 | |a McLeod, Lisa |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zhao, Xin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Walter, Ashley |e VerfasserIn |4 aut | |
| 700 | 1 | |a Da Costa, Daniel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Manley, Peter |e VerfasserIn |4 aut | |
| 700 | 1 | |a Blackman, Samuel C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Packer, Roger J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nysom, Karsten |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature medicine |d [New York, NY] : Springer Nature, 1995 |g 30(2024), 1 vom: Jan., Seite 207-217 |h Online-Ressource |w (DE-627)301511640 |w (DE-600)1484517-9 |w (DE-576)288571274 |x 1546-170X |7 nnas |a The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma the phase 2 FIREFLY-1 trial |
| 773 | 1 | 8 | |g volume:30 |g year:2024 |g number:1 |g month:01 |g pages:207-217 |g extent:11 |a The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma the phase 2 FIREFLY-1 trial |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s41591-023-02668-y |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.nature.com/articles/s41591-023-02668-y |x Verlag |z lizenzpflichtig |3 Volltext |
| 883 | |8 1\p |a cgwrk |d 20250301 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 2\p |a cgwrk |d 20250301 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 951 | |a AR | ||
| 992 | |a 20240207 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 17275030X |a Witt, Olaf |m 17275030X:Witt, Olaf |d 910000 |d 910500 |e 910000PW17275030X |e 910500PW17275030X |k 0/910000/ |k 1/910000/910500/ |p 13 | ||
| 999 | |a KXP-PPN1880184710 |e 4478538980 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title":"The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma","subtitle":"the phase 2 FIREFLY-1 trial","title_sort":"type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma"}],"physDesc":[{"extent":"11 S."}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Nature medicine","title":"Nature medicine"}],"part":{"text":"30(2024), 1 vom: Jan., Seite 207-217","volume":"30","year":"2024","pages":"207-217","issue":"1","extent":"11"},"pubHistory":["1.1995 -"],"note":["Gesehen am 24. Juli 2018"],"language":["eng"],"disp":"The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma the phase 2 FIREFLY-1 trialNature medicine","origin":[{"publisher":"Springer Nature ; Nature America Inc.","dateIssuedDisp":"2017-","dateIssuedKey":"2017","publisherPlace":"[New York, NY] ; New York, NY"}],"id":{"zdb":["1484517-9"],"eki":["301511640"],"issn":["1546-170X"]},"recId":"301511640","type":{"media":"Online-Ressource","bibl":"periodical"}}],"origin":[{"dateIssuedDisp":"January 2024","dateIssuedKey":"2024"}],"name":{"displayForm":["Lindsay B. Kilburn, Dong-Anh Khuong-Quang, Jordan R. Hansford, Daniel Landi, Jasper van der Lugt, Sarah E.S. Leary, Pablo Hernáiz Driever, Simon Bailey, Sébastien Perreault, Geoffrey McCowage, Angela J. Waanders, David S. Ziegler, Olaf Witt, Patricia A. Baxter, Hyoung Jin Kang, Timothy E. Hassall, Jung Woo Han, Darren Hargrave, Andrea T. Franson, Michal Yalon Oren, Helen Toledano, Valérie Larouche, Cassie Kline, Mohamed S. Abdelbaki, Nada Jabado, Nicholas G. Gottardo, Nicolas U. Gerber, Nicholas S. Whipple, Devorah Segal, Susan N. Chi, Liat Oren, Enrica E.K. Tan, Sabine Mueller, Izzy Cornelio, Lisa McLeod, Xin Zhao, Ashley Walter, Daniel Da Costa, Peter Manley, Samuel C. Blackman, Roger J. Packer & Karsten Nysom"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"recId":"1880184710","id":{"doi":["10.1038/s41591-023-02668-y"],"eki":["1880184710"]},"person":[{"given":"Lindsay B.","family":"Kilburn","role":"aut","display":"Kilburn, Lindsay B."},{"given":"Dong-Anh","display":"Khuong-Quang, Dong-Anh","role":"aut","family":"Khuong-Quang"},{"role":"aut","family":"Hansford","display":"Hansford, Jordan R.","given":"Jordan R."},{"given":"Daniel","family":"Landi","role":"aut","display":"Landi, Daniel"},{"family":"van der Lugt","role":"aut","display":"van der Lugt, Jasper","given":"Jasper"},{"family":"Leary","role":"aut","display":"Leary, Sarah E. S.","given":"Sarah E. S."},{"role":"aut","family":"Driever","display":"Driever, Pablo Hernáiz","given":"Pablo Hernáiz"},{"given":"Simon","role":"aut","family":"Bailey","display":"Bailey, Simon"},{"given":"Sébastien","family":"Perreault","role":"aut","display":"Perreault, Sébastien"},{"role":"aut","family":"McCowage","display":"McCowage, Geoffrey","given":"Geoffrey"},{"display":"Waanders, Angela J.","role":"aut","family":"Waanders","given":"Angela J."},{"family":"Ziegler","role":"aut","display":"Ziegler, David S.","given":"David S."},{"family":"Witt","role":"aut","display":"Witt, Olaf","given":"Olaf"},{"given":"Patricia A.","family":"Baxter","role":"aut","display":"Baxter, Patricia A."},{"given":"Hyoung Jin","display":"Kang, Hyoung Jin","role":"aut","family":"Kang"},{"given":"Timothy E.","display":"Hassall, Timothy E.","role":"aut","family":"Hassall"},{"display":"Han, Jung Woo","family":"Han","role":"aut","given":"Jung Woo"},{"display":"Hargrave, Darren R.","family":"Hargrave","role":"aut","given":"Darren R."},{"given":"Andrea T.","family":"Franson","role":"aut","display":"Franson, Andrea T."},{"family":"Yalon Oren","role":"aut","display":"Yalon Oren, Michal","given":"Michal"},{"role":"aut","family":"Toledano","display":"Toledano, Helen","given":"Helen"},{"given":"Valérie","display":"Larouche, Valérie","role":"aut","family":"Larouche"},{"given":"Cassie","display":"Kline, Cassie","role":"aut","family":"Kline"},{"display":"Abdelbaki, Mohamed S.","role":"aut","family":"Abdelbaki","given":"Mohamed S."},{"given":"Nada","display":"Jabado, Nada","family":"Jabado","role":"aut"},{"family":"Gottardo","role":"aut","display":"Gottardo, Nicholas G.","given":"Nicholas G."},{"given":"Nicolas U.","display":"Gerber, Nicolas U.","family":"Gerber","role":"aut"},{"given":"Nicholas S.","display":"Whipple, Nicholas S.","family":"Whipple","role":"aut"},{"given":"Devorah","display":"Segal, Devorah","family":"Segal","role":"aut"},{"display":"Chi, Susan N.","role":"aut","family":"Chi","given":"Susan N."},{"display":"Oren, Liat","role":"aut","family":"Oren","given":"Liat"},{"family":"Tan","role":"aut","display":"Tan, Enrica E. K.","given":"Enrica E. K."},{"given":"Sabine","family":"Müller","role":"aut","display":"Müller, Sabine"},{"display":"Cornelio, Izzy","family":"Cornelio","role":"aut","given":"Izzy"},{"given":"Lisa","display":"McLeod, Lisa","family":"McLeod","role":"aut"},{"family":"Zhao","role":"aut","display":"Zhao, Xin","given":"Xin"},{"given":"Ashley","role":"aut","family":"Walter","display":"Walter, Ashley"},{"role":"aut","family":"Da Costa","display":"Da Costa, Daniel","given":"Daniel"},{"given":"Peter","family":"Manley","role":"aut","display":"Manley, Peter"},{"given":"Samuel C.","display":"Blackman, Samuel C.","role":"aut","family":"Blackman"},{"role":"aut","family":"Packer","display":"Packer, Roger J.","given":"Roger J."},{"display":"Nysom, Karsten","role":"aut","family":"Nysom","given":"Karsten"}],"language":["eng"],"note":["Veröffentlicht: 17. November 2023","Gesehen am 07.02.2024"]} | ||
| SRT | |a KILBURNLINTYPEIIRAFI2024 | ||